FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2215652045> ?p ?o ?g. }

• W2215652045 endingPage "26" @default.
• W2215652045 startingPage "611" @default.
• W2215652045 abstract "Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide (1). Most patients present with intermediate or advanced disease that is not amenable to curative treatment, and the median survival in this group is 6-8 months (2). Several studies and well-designed randomized trials have shown a positive effect of transcatheter arterial chemoembolization (TACE) on patient outcome and survival (3-8). As nicely described in the present article from Wang et al. , assessment of tumor response is of extreme importance in patients undergoing locoregional treatments of liver cancer (9). Early assessment of the effectiveness of TACE and monitoring of tumor response are paramount to the identification of treatment failure, guidance of future therapy, and determination of the interval for repeat treatment. Wang et al. confirm in this article that imaging evaluation of HCC response to therapy is generally and widely performed with cross-sectional imaging [computed tomography (CT) and magnetic resonance imaging (MRI)] by using the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria and the European Association for the Study of the Liver (EASL) criteria which have been introduced in the past decade (9). It is interesting to note that these criteria are not based on experimental or observational studies, but are proposed as revised versions of World Health Organization (WHO) and RECIST criteria (10-13). Initial reports showed that they were better than the latter for assessment of response, and both have been shown to be independent prognostic factors (14-19). Nevertheless, these criteria have been shown to have several limitations, mainly the lack of standardization, and there are concerns about applicability and reproducibility that have been raised. Indeed, they may be difficult to use, especially in heterogeneous lesions, and their use is dependent on operator experience. Although recent guidelines have acknowledged the potential value of these new criteria, they are not considered robust enough to replace older morphological criteria in trials (18). As a result, since they were first introduced, numerous studies have been published to better define the type and optimal number of target lesions, the ideal imaging technique, and the follow-up schedule. At present most teams perform one-dimensional mRECIST or two-dimensional EASL measurement of the enhanced portion of a maximum of two target lesions (18,19). Nevertheless, very recent data have suggested that three-dimensional (3D) evaluation of the whole tumor burden using specific software, functional imaging or cone-beam CT (CBCT) imaging may be of interest as novel imaging biomarkers to predict future tumor response to TACE in HCC patients (10,20-27)." @default.
• W2215652045 created "2016-06-24" @default.
• W2215652045 creator A5007985874 @default.
• W2215652045 creator A5030985674 @default.
• W2215652045 creator A5051192832 @default.
• W2215652045 creator A5070781631 @default.
• W2215652045 date "2015-12-01" @default.
• W2215652045 modified "2023-09-23" @default.
• W2215652045 title "Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients." @default.
• W2215652045 cites W1484303 @default.
• W2215652045 cites W1584669207 @default.
• W2215652045 cites W1919225037 @default.
• W2215652045 cites W1929342880 @default.
• W2215652045 cites W1966218436 @default.
• W2215652045 cites W1966648862 @default.
• W2215652045 cites W1968732051 @default.
• W2215652045 cites W1972296793 @default.
• W2215652045 cites W1974036023 @default.
• W2215652045 cites W1982863393 @default.
• W2215652045 cites W1990026158 @default.
• W2215652045 cites W1997239947 @default.
• W2215652045 cites W2000390268 @default.
• W2215652045 cites W2010265466 @default.
• W2215652045 cites W2012305641 @default.
• W2215652045 cites W2016770637 @default.
• W2215652045 cites W2019607817 @default.
• W2215652045 cites W2020215421 @default.
• W2215652045 cites W2020465877 @default.
• W2215652045 cites W2026582121 @default.
• W2215652045 cites W2032025076 @default.
• W2215652045 cites W2036354953 @default.
• W2215652045 cites W2039895335 @default.
• W2215652045 cites W2040585172 @default.
• W2215652045 cites W2041454087 @default.
• W2215652045 cites W2052552898 @default.
• W2215652045 cites W2053755320 @default.
• W2215652045 cites W2065397650 @default.
• W2215652045 cites W2068283599 @default.
• W2215652045 cites W2072209368 @default.
• W2215652045 cites W2079586464 @default.
• W2215652045 cites W2086576764 @default.
• W2215652045 cites W2090401006 @default.
• W2215652045 cites W2092759077 @default.
• W2215652045 cites W2093580610 @default.
• W2215652045 cites W2096660011 @default.
• W2215652045 cites W2100417237 @default.
• W2215652045 cites W2103637700 @default.
• W2215652045 cites W2104414799 @default.
• W2215652045 cites W2117589590 @default.
• W2215652045 cites W2119671639 @default.
• W2215652045 cites W2120334622 @default.
• W2215652045 cites W2122754781 @default.
• W2215652045 cites W2123007095 @default.
• W2215652045 cites W2123036383 @default.
• W2215652045 cites W2125763116 @default.
• W2215652045 cites W2131456570 @default.
• W2215652045 cites W2131753824 @default.
• W2215652045 cites W2133224992 @default.
• W2215652045 cites W2137052325 @default.
• W2215652045 cites W2139010205 @default.
• W2215652045 cites W2139213474 @default.
• W2215652045 cites W2139248078 @default.
• W2215652045 cites W2139549012 @default.
• W2215652045 cites W2141693069 @default.
• W2215652045 cites W2148944511 @default.
• W2215652045 cites W2152517685 @default.
• W2215652045 cites W2153935627 @default.
• W2215652045 cites W2164507773 @default.
• W2215652045 cites W2170439881 @default.
• W2215652045 cites W2171541744 @default.
• W2215652045 cites W3148676889 @default.
• W2215652045 cites W4245784696 @default.
• W2215652045 doi "https://doi.org/10.3978/j.issn.1000-9604.2015.07.02" @default.
• W2215652045 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4697100" @default.
• W2215652045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26752936" @default.
• W2215652045 hasPublicationYear "2015" @default.
• W2215652045 type Work @default.
• W2215652045 sameAs 2215652045 @default.
• W2215652045 citedByCount "0" @default.
• W2215652045 crossrefType "journal-article" @default.
• W2215652045 hasAuthorship W2215652045A5007985874 @default.
• W2215652045 hasAuthorship W2215652045A5030985674 @default.
• W2215652045 hasAuthorship W2215652045A5051192832 @default.
• W2215652045 hasAuthorship W2215652045A5070781631 @default.
• W2215652045 hasConcept C121608353 @default.
• W2215652045 hasConcept C126322002 @default.
• W2215652045 hasConcept C126838900 @default.
• W2215652045 hasConcept C143409427 @default.
• W2215652045 hasConcept C143998085 @default.
• W2215652045 hasConcept C146357865 @default.
• W2215652045 hasConcept C151730666 @default.
• W2215652045 hasConcept C168563851 @default.
• W2215652045 hasConcept C23131810 @default.
• W2215652045 hasConcept C2776231280 @default.
• W2215652045 hasConcept C2778019345 @default.
• W2215652045 hasConcept C2778455285 @default.
• W2215652045 hasConcept C2778822529 @default.
• W2215652045 hasConcept C2779134260 @default.

• next